You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 11, 2024

CLINICAL TRIALS PROFILE FOR SERLOPITANT

✉ Email this page to a colleague

« Back to Dashboard

Clinical Trials for Serlopitant

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Summary
NCT01951274 ↗	VPD-737 for Treatment of Chronic Pruritus	Completed	Menlo Therapeutics Inc.	Phase 2	A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments
NCT01951274 ↗	VPD-737 for Treatment of Chronic Pruritus	Completed	Vyne Therapeutics Inc.	Phase 2	A study of a several doses of a novel treatment for chronic itch compared to placebo for patients whose condition has not responded to other treatments
NCT02196324 ↗	A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)	Completed	Menlo Therapeutics Inc.	Phase 2	The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
NCT02196324 ↗	A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)	Completed	Vyne Therapeutics Inc.	Phase 2	The purpose of this study is to demonstrate whether or not VPD-737, an NK1 receptor antagonist is safe and effective for treatment of prurigo nodularis versus placebo.
NCT02654483 ↗	Neurokinin-1 Receptor Antagonist for the Treatment of Itch in EB Patients	Completed	Epidermolysis Bullosa Research Partnership	Phase 2	Our goal is to determine whether daily oral administration of VPD-737 (5 mg) is effective and safe in treating moderate to severe pruritus in patients with Epidermolysis Bullosa (EB).
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Summary

Clinical Trial Conditions for Serlopitant

Condition Name

Chart
Table

Condition Name
Intervention	Trials
Pruritus	8
Prurigo Nodularis	4
Epidermolysis Bullosa	2
Psoriasis	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH
Intervention	Trials
Pruritus	10
Prurigo	4
Neurodermatitis	3
Dermatitis, Atopic	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for Serlopitant

Trials by Country

Map
Table

Trials by Country
Location	Trials
United States	152
Germany	3
Poland	2
Austria	2
United Kingdom	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State
Location	Trials
California	9
Florida	8
North Carolina	7
New York	7
New Jersey	7
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for Serlopitant

Clinical Trial Phase

Chart
Table

Clinical Trial Phase
Clinical Trial Phase	Trials
Phase 3	3
Phase 2	9
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status
Clinical Trial Phase	Trials
Completed	9
Terminated	2
Recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Serlopitant

Sponsor Name

Chart
Table

Sponsor Name
Sponsor	Trials
Vyne Therapeutics Inc.	11
Menlo Therapeutics Inc.	11
Epidermolysis Bullosa Research Partnership	2
[disabled in preview]	2
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type
Sponsor	Trials
Industry	22
Other	5
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.